SkinBioTherapeutics Plc (LON:SBTX) CEO Dr. Cath O’Neill talks to DirectorsTalk about the progress made since FY results in October 17. Cath provides us with an update, reminds us what SkinBioTherapeutics does and how its SkinBiotix® technology works, areas of skin health focused on, the significance of the successful scale-up and formulation, next milestones, other programmes and getting to market and progress on possible commercial partners.
SkinBioTherapeutics Plc is a life science company focused on skin health. The Company’s proprietary platform technology, SkinBiotix®, is based upon discoveries made by CEO Dr. Cath O’Neill and Professor Andrew McBain.
The company platform applies research discoveries made on the activities of lysates derived from probiotic bacteria when applied to the skin. The Company has shown that the SkinBiotix® platform can improve the barrier effect of skin models, protect skin models from infection and repair skin models. Proof of principle studies have shown that the SkinBiotix® platform has beneficial attributes applicable to each of these areas.